Understanding CDKL5 Deficiency Disorder
CDKL5 Deficiency Disorder (CDD) is a rare genetic neurological condition that begins in early infancy and significantly affects development, movement, and seizure control.
What is CDKL5?
CDKL5 Deficiency Disorder is caused by a mutation in the CDKL5 gene, which plays a critical role in early brain development. This gene is located on the X chromosome and is essential for normal neurological function.
When the CDKL5 gene does not function properly, it disrupts how brain cells communicate and develop. As a result, children with CDD experience early-onset seizures and significant developmental challenges.
Although CDKL5 is more commonly diagnosed in girls, boys can also be affected. Each child’s journey is unique, and symptoms can vary widely in severity.
Common Symptoms & Challenges
- Early-onset, difficult-to-control seizures
- Global developmental delays
- Limited or absent speech
- Motor and movement difficulties
- Low muscle tone or stiffness
- Feeding and swallowing challenges
- Sleep disturbances
- Vision and communication difficulties
Current Treatment Landscape
At present, there is no cure for CDKL5 Deficiency Disorder. Available treatments focus on managing symptoms rather than addressing the underlying genetic cause.
Seizures are often treated with anti-epileptic medications, though many children continue to experience seizures despite multiple therapies. Supportive treatments such as physiotherapy, occupational therapy, speech therapy, and nutritional support play an important role in improving quality of life.
Research & Future Therapies
CDKL5 Deficiency Disorder is caused by a single-gene mutation, making it a strong candidate for gene replacement therapy.
A dedicated gene therapy program is already in development. Advancing this program through regulatory milestones and into clinical trials requires sustained funding, scientific rigor, and collaborative effort.
Continued research represents a critical pathway toward meaningful, long-term treatment options for children and families affected by CDKL5.
Clinical Trials & Emerging Therapies
Clinical trials are essential for advancing new treatments for CDKL5 Deficiency Disorder. CDKL5 South Asia Foundation coordinates recruitment for the CDKL5 Gene Therapy Clinical Trial Recruitment Program and also shares information about other ongoing clinical trials relevant to the rare disease community, including the CDKL2 Clinical Trial.
CDKL5 Gene Therapy Recruitment
Families of patients diagnosed with CDKL5 Deficiency Disorder can apply for screening through our Clinical Trial Recruitment Program. Applications help evaluate preliminary eligibility based on the study's inclusion and exclusion criteria.
Apply for Clinical Trial Screening →CDKL2 Clinical Trial
Learn more about the ongoing CDKL2 Clinical Trial, its scientific background, current status, and why it is of interest to families following advances in genetic neurological disorders.
Learn About the CDKL2 Clinical Trial →